May 19, 2026

OT VIII Bob Duggan, the majority stockholder of his company Summit Therapeutics Inc. (SMMT) has watched roughly $7.6 billion of his personal paper wealth evaporate.

When added to the Summit stock his wife and Summit’s Co-CEO Dr. Mahkam “Maky” Zanganeh owns, the couple has lost approximately $8.3 billion following Summit’s precipitous stock collapse from its 52-week high of $30.98 to $15.85, a decline of $15.13 per share or 48.8 percent.

The $8.3 billion Bob Duggan and his wife Maky Zanganeh have lost is the largest statcrash in the entire 76-year history of Scientology.

The $8.3 billion loss is larger than the entire net worth of the Church of Scientology itself.

Summit’s total market-capitalization loss from the 52-week high is approximately $11.7 billion against the 776,162,645 shares of common stock outstanding as of April 24, 2026.

I want to be precise about the numbers, because the doctrinal points about Scientology I am going to make turn on the numbers.

Summit’s most recent definitive proxy statement, filed April 17, 2026, reports that Robert W. Duggan beneficially owns 499,428,667 shares of Summit common stock, or 67.8 percent of the class, as of the April 15, 2026 record date.

That total comprises 480,074,925 shares held directly and 19,353,742 shares held by the Boundless Saint Charitable Trust, for which Duggan serves as trustee.

Dr. Mahkam Zanganeh, Duggan’s wife and Summit’s Co-CEO, separately holds 51,032,750 shares, or 6.9 percent of the class. The Duggan-Zanganeh household therefore beneficially owns 550,461,417 shares, or 74.8 percent of the class — a level of insider concentration that explains why the household’s paper-wealth swing is essentially indistinguishable from Summit’s market-capitalization swing.

Scroll down to read SMMT April 2026 Form 10-Q which shows ownership of SMMT stock.

L. Ron Hubbard’s Ethics Technology — Stats, Upstats, Downstats, and Statcrashers

To understand the title I have given Duggan in this post, the reader needs a brief primer on L. Ron Hubbard’s Ethics technology. In Scientology, every activity in life — and in particular every activity inside the church, every staff post, and every Scientologist’s business — is measured by a statistic, or stat.

A stat is a numerical measurement of production. Hubbard taught that stats are the only honest measure of a being’s worth, and that every Scientologist, every staff member, and every executive should be evaluated — promoted, rewarded, demoted, or disciplined — on the basis of their stats.

A Scientologist whose stats are rising week over week is an upstat; a Scientologist whose stats are falling week over week is a downstat.

A catastrophic, sudden collapse of stats — the kind of vertical drop that cannot be explained by ordinary week-to-week variance — is, in Hubbard’s exact terminology, a statcrash.

Bob Duggan is the most prominent OT VIII Scientologist on the public corporate stage. He is, by his own profession of faith, a being who has completed Hubbard’s highest publicly delivered level of spiritual auditing and who is therefore, by Scientology’s own doctrine, supposed to be capable of producing stats that climb in a straight line forever.

The Summit Therapeutics stock chart over the past twelve months is, in Hubbard’s own technical vocabulary, a textbook statcrash. From $30.98 to $15.85 is not a downstat. It is a statcrash. And Bob Duggan pulled it in:

The Ethics Condition of Confusion

Hubbard’s Ethics technology does not stop at measurement. It prescribes a remedy. For every level of statistical performance, Hubbard assigned an Ethics Condition, and for every condition he wrote a formula — a sequence of mandatory steps a Scientologist must apply in order to climb back up the conditions ladder.

From the bottom up, the conditions are Confusion, Treason, Enemy, Doubt, Liability, Non-Existence, Danger, Emergency, Normal, Affluence, and Power.

The lowest condition — the one assigned when a being’s stats have collapsed so completely that the being can no longer even identify what is happening or what to do about it — is the Condition of Confusion.

By Scientology’s own doctrine, Bob Duggan is now in the Condition of Confusion. From Scientology’s website:

The ethics condition of Confusion is so low in Scientology that a Scientologist in this condition must “word clear” the word Confusion by looking it up in a dictionary to even know what “Confusion” means. Hubbard requires Scientologists in Confusion to understand what Confusion means.

The formula for Confusion: Find out where you are.

According to Hubbard’s doctrine, Bob Duggan’s statcrash at Summit means that he does not even know where he is.

In order to work his way out of Confusion, Duggan has to discover where he is.

Bob Duggan is an OT VIII and the majority stockholder of a public biotech company whose Phase III ivonescimab data was supposed to be a once-in-a-generation Keytruda-killer.

Keytruda is a potent and effect immunotherapy medication used to treat over 40 different types of cancer. As such, it generates billions of dollars in profit annually.

Bob Duggan’s competitive drug is called “Ivonescimab” and it was supposed to outperform Keytruda. However, the clinical trials have not yielded the expected results. The lack of clinical results is a major part of the plunge in Summit’s stock price. 

Duggan licensed the rights to Ivonescimab from a Chinese company that is ultimately controlled by the Chinese Communist Party as are all companies in China. Why Duggan chose to pay $500 million in licensing rights to a CCP-controlled entity suggests that he was already in a condition of Confusion when he made the deal and later regretted it.

The Janssen Trade Secrets Case 

On April 30, 2026 — the same day Summit’s auditor issued the qualified opinion expressing substantial doubt about Summit’s ability to continue as a going concern — the company also disclosed for the first time the existence of a federal trade secrets case in which it is named as the destination employer of the defendant.

The case is Janssen Global Services, LLC v. Cynthia Nwachukwu, Case No. 3:26-cv-02563-MAS-TJB, filed in the United States District Court for the District of New Jersey on March 12, 2026.

Janssen — the pharmaceutical division of Johnson & Johnson — alleges that its former Associate Director of Global Medical Affairs downloaded thousands of confidential files from Janssen’s systems during the months preceding her November 1, 2025 resignation, and is now, on Janssen’s information and belief, employed by Summit. Janssen’s prayer for relief asks the court to enjoin the defendant from using Janssen’s confidential information “in connection with” Summit Therapeutics, among other competitive businesses.

The therapeutic-area overlap is direct and material: Janssen markets amivantamab (RYBREVANT), a bispecific antibody used in the treatment of EGFR-mutant non-small cell lung cancer, the same indication in which Summit is developing ivonescimab and the same indication on which Summit’s November 14, 2026 PDUFA date depends.

On May 11, 2026, Magistrate Judge Tonianne J. Bongiovanni so-ordered a Stipulated Confidentiality and Protective Order whose terms — a two-tier Attorney Eyes Only regime, a same-therapeutic-area Competitor exclusion, an artificial intelligence and machine learning training prohibition, and a categorical litigation funder exclusion referencing the Foreign Agents Registration Act and the Department of Justice Data Security Program — describe the architecture of a case in which both sides expect serious, contested, document-intensive proceedings.

Summit is not a defendant in the case. Summit’s commercial activities are, however, the destination at which Janssen’s requested injunctive relief is aimed. The full analysis of the protective order’s four operative provisions is at the Scientology Money Project’s May 19, 2026 piece, OT8 Bob Duggan’s Summit Therapeutics Named as Defendant’s Current Employer in Federal Trade Secrets Case: Court Enters Protective Order in Janssen v. Nwachukwu.

Market Chameleon: Dead Cat Bounce and IV30 IV Rank of 98 Percent Elevated 

Market Chameleon, the options-analytics platform widely used by professional traders, currently classifies SMMT’s recent price action as a Dead Cat Bounce — the technical-analysis term for a brief, shallow recovery inside an otherwise sustained downtrend, named for the trader’s mordant observation that even a dead cat will bounce if it is dropped from a sufficient height. From Market Chameleon today May 19, 2026: 

The Dead Cat Bounce designation is not a forecast; it is a pattern-recognition label applied to charts that have already declined sharply and are now producing a counter-trend rally that the platform’s algorithm does not expect to hold. A Dead Cat Bounce is not investment advice. 

From Investopedia:

A dead cat bounce is a rally that is unsupported by fundamentals that is reversed by price movement to the downside.

In technical analysis, a dead cat bounce is considered to be a continuation pattern.

At first, the bounce may appear to be a reversal of the prevailing trend, but it is quickly followed by a continuation of the downward price move.

Dead cat bounce patterns are usually only realized after the fact and are difficult to identify in real-time.

Market Chameleon also reports SMMT’s 30-day implied volatility (IV30) at an IV Rank of 98 percent, which the platform labels Elevated. IV Rank measures where the current implied volatility sits relative to the security’s own trailing 52-week IV range, on a scale of 0 to 100.

An IV Rank of 98 means that SMMT’s options market is pricing in near-the-top-of-its-own-range expected price movement — the options market itself is telling us that Summit is now, by its own historical standard, an exceptionally turbulent stock.

The SEC Form 10-Q filed by Summit Therapeutics in April 2026 shows the shares held by Bob Duggan, Maky Zanganeh, and the Boundless Saint Charitable Trust where Duggan serves as a trustee: